A propellant utilization system for a space vehicle having at least a first thrust source and a second thrust source. The propellant utilization system utilizes a common set of algorithms to generate mixture ratios for each thrust source as each thrust source becomes active. The propellant utilizati
A propellant utilization system for a space vehicle having at least a first thrust source and a second thrust source. The propellant utilization system utilizes a common set of algorithms to generate mixture ratios for each thrust source as each thrust source becomes active. The propellant utilization system includes a processing system comprising sequencer logic, propellant logic, and mixture ratio logic. The sequencer logic determines when a thrust source is active, e.g. one of the first and second thrust sources, and provides flight parameters for the active thrust source to the propellant logic and the mixture ratio logic. The propellant logic processes information from propellant sources connected to the active thrust source, using the flight parameters for that thrust source, to determine an amount of remaining propellant in each source. The mixture ratio logic generates a mixture ratio for the active thrust source, using the flight parameters for that thrust source and information on the remaining amount of propellant in the in each source connected to the active thrust source.
대표청구항▼
A propellant utilization system for a space vehicle having at least a first thrust source and a second thrust source. The propellant utilization system utilizes a common set of algorithms to generate mixture ratios for each thrust source as each thrust source becomes active. The propellant utilizati
A propellant utilization system for a space vehicle having at least a first thrust source and a second thrust source. The propellant utilization system utilizes a common set of algorithms to generate mixture ratios for each thrust source as each thrust source becomes active. The propellant utilization system includes a processing system comprising sequencer logic, propellant logic, and mixture ratio logic. The sequencer logic determines when a thrust source is active, e.g. one of the first and second thrust sources, and provides flight parameters for the active thrust source to the propellant logic and the mixture ratio logic. The propellant logic processes information from propellant sources connected to the active thrust source, using the flight parameters for that thrust source, to determine an amount of remaining propellant in each source. The mixture ratio logic generates a mixture ratio for the active thrust source, using the flight parameters for that thrust source and information on the remaining amount of propellant in the in each source connected to the active thrust source. ls for use with the derived measure of the EEG signal complexity in controlling the administration of the hypnotic drug to the patient. 12. The method according to claim 1 further including the steps of establishing desired cardiovascular characteristics for the patient; obtaining cardiovascular data from the patient; comparing the cardiovascular data of the patient to desired cardiovascular characteristics; and further controlling the administration of the hypnotic drug in accordance with the comparison of cardiovascular characteristics and data. 13. The method according to claim 1 further including the step of establishing a transfer function between the pharmacological effects of the hypnotic drug in the patient and the administration of the drug to the patient for use in controlling the drug administration. 14. The method according to claim 1 further including the step of employing a pharmacokinetic model in controlling the administration of the drug to the patient. 15. The method according to claim 1 further including the step of employing a pharmacodynamic model in controlling administration of the drug to the patient. 16. The method according to claim 15 further including the step of employing a pharmacokinetic model in controlling the administration of the drug to the patient. 17. The method according to claim 13 further including the step of employing a pharmacokinetic model in establishing the transfer function for controlling the administration of the drug to the patient. 18. The method according to claim 13 further including the step of employing a pharmacodynamic model in establishing the transfer function for controlling administration of the drug to the patient. 19. The method according to claim 17 further including the step of employing a pharmacodynamic model in establishing the transfer function for controlling administration of the drug to the patient. 20. The method according to claim 1 further including the step of measuring amounts of volatile hypnotic drugs in breathing gases in the patient and controlling the administration of the hypnotic drugs in accordance with the volatile drug measurement. 21. The method according to claim 13 further including the step of measuring amounts of volatile hypnotic drugs in breathing gases in the patient and as employing the measurement in establishing the transfer function for use in controlling the administration of the drug. 22. The method according to claim 13 further including the steps of obtaining cardiovascular data from the patient and as employing the cardiovascular data in establishing the transfer function for use in controlling the administration of the hypnotic drug. 23. The method according to claim 1 further including the step of providing information relating to one or more of the patient, the hypnotic drug, a medical procedure, and a physician for use in controlling the administration of the hypnotic drug to the patient. 24. The method according to claim 1 further including the step of storing information relating to one or more of the patient, the hypnotic drug, a medical procedure, and a physician for use in controlling the administration of the hypnotic drug to the patient. 25. The method according to claim 24 wherein the stored information includes information relating to a previous anesthetization of the patient. 26. The method according to claim 23 further including the step of storing information relating to one or more of the patient, the hypnotic drug, a medical procedure, and a physician and as employing the stored information in controlling the administration of the hypnotic drug to the patient. 27. The method according to claim 1 including the step of generating information in the course of an anesthetization and employing the generated information in controlling the administration of the hypnotic drug to the patient. 28. Apparatus for administering an hypnotic drug to a patient, said apparatus comprising: (a) means for establishing a si gnal corresponding to a desired hypnotic level for the patient; (b) an anesthetic delivery unit for administering the hypnotic drug to the patient; (c) a sensor for obtaining EEG signal data from the patient; (d) means coupled to said sensor for deriving at least one measure of the complexity of the EEG signal data, for determining the hypnotic level existing in the patient from the complexity of the EEG signal data, and for providing a signal corresponding to same; and (e) a control unit including a comparator having inputs coupled to said elements (a) and (c) and an output coupled to element (b), said comparator comparing the signals corresponding to the hypnotic level existing in the patient and the signal corresponding to the desired hypnotic level and providing an output signal for controlling the anesthetic delivery unit and the administration of the hypnotic drug in accordance with the comparison. 29. The apparatus according to claim 28 wherein element (d) is further defined as means for measuring an entropy of the EEG data to determine the hypnotic level existing in the patient. 30. The apparatus according to claim 29 wherein element (d) is further defined as means for measuring the spectral entropy of the EEG signal data. 31. The apparatus according to claim 29 wherein element (d) is further defined as means for measuring the approximate entropy of the EEG signal data. 32. The apparatus according to claim 28 wherein element (d) is further defined as means employing a Lempel-Ziv complexity measure to determine the hypnotic level existing in the patient. 33. The apparatus according to claim 28 wherein element (d) is further defined as means for carrying out a fractal spectrum analysis to measure the complexity of the EEG signal data to determine the hypnotic level existing in the patient. 34. The apparatus according to claim 28 wherein element (d) is further defined as deriving a plurality of EEG signal data complexity measures for determining the hypnotic level existing in the patient. 35. The apparatus according to claim 28 wherein element (c) is further defined as a sensor for obtaining EEG signals resulting from the cerebral activity of the patient and element (d) is further defined as using EEG signals in providing the signal corresponding to the hypnotic level existing in the patient. 36. The apparatus according to claim 35 wherein element (c) is further defined as a sensor for obtaining EMG signals resulting from the muscle activity of the patient and element (d) is further defined as deriving a measure of EMG activity from the EMG signals and using same with a measure derived from EEG signal complexity to provide the signal corresponding to the hypnotic level in the patient. 37. The apparatus according to claim 36 wherein element (d) is further defined as means for obtaining a frequency domain power spectrum of the EMG signals to derive the measure of EMG activity in the patient. 38. The apparatus according to claim 35 wherein element (c) is further defined as a sensor for obtaining EMG signals resulting from the muscle activity of the patient and element (d) is further defined as means for deriving the complexity of the EEG signal data over a frequency spectrum incorporating the EEG signals and EMG signals for use with a derived measure of EEG signal complexity to determine the hypnotic level of the patient. 39. The apparatus according to claim 28 further including means for providing a signal corresponding to desired cardiovascular characteristics for the patient; means for obtaining cardiovascular signal data from the patient; means for comparing the cardiovascular signal data of the patient to desired cardiovascular characteristic signal; and means for controlling the anesthetic delivery unit and the administration of the hypnotic drug in accordance with the comparison of the cardiovascular characteristics signal and cardiovascular signal data. 40. The apparatus according to claim 28 further including means in said control unit for establishing a transfer function between the pharmacological effects in the patient and the administration of the drug to the patient for use in controlling said anesthetic delivery unit. 41. The apparatus according to claim 28 further including pharmacokinetic model means in said control unit for use in controlling operation of said anesthetic delivery unit. 42. The apparatus according to claim 28 further including pharmacodynamic model means in said control unit for use in controlling operation of said anesthetic delivery unit. 43. The apparatus according to claim 42 further including pharmacokinetic model means in said control unit for use in controlling the operation of said anesthetic delivery unit. 44. The apparatus according to claim 40 further including pharmacokinetic model means for use with said transfer function means in controlling the operation of said anesthetic delivery unit. 45. The apparatus according to claim 40 further including pharmacodynamic model means in said control unit for use with said transfer function means in controlling the operation of said anesthetic delivery unit. 46. The apparatus according to claim 44 further including pharmacodynamic model means in said control unit for use with said transfer function means in controlling the operation of said anesthetic delivery unit. 47. The apparatus according to claim 28 further including means for measuring amounts of volatile hypnotic drugs in the breathing gases in the patient and coupled to said control unit for use in controlling the anesthetic delivery unit. 48. The apparatus according to claim 40 further including means for measuring amounts of volatile hypnotic drugs in the breathing gases to the patient, said means being coupled to said transfer function means for use in establishing the transfer function. 49. The apparatus according to claim 40 further including means for obtaining cardiovascular data from the patient, said means being coupled to said transfer function means for use in establishing the transfer function. 50. The apparatus according to claim 28 further including means for providing information relating to one or more of the patient, the hypnotic drug, a medical procedure, and a physician for use in controlling the administration of the hypnotic drug to the patient. 51. The apparatus according to claim 50 further including storage means for storing information relating to one or more of the patient, the hypnotic drug, a medical procedure, and a physician for use in controlling the administration of the hypnotic drug to the patient. 52. The apparatus according to claim 51 wherein the storage means stores information relating to a previous anesthetization of the patient. 53. The apparatus according to claim 50 further including storage means for storing information relating to one or more of the patient, the hypnotic drug, a medical procedure, and a physician for use in controlling the administration of the hypnotic drug to the patient. 54. The apparatus according to claim 28 including means for generating information in the course of an anesthetization and for employing the generated information in controlling the administration of the hypnotic drug to the patient.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (6)
Mango Frank, Anti-slosh liquid propellant tank for launch vehicles.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.